Camrelizumab

Generic Name
Camrelizumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1798286-48-2
Unique Ingredient Identifier
73096E137E
Background

Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Indication

⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。

⑵用于霍奇金淋巴瘤(三线)、肝细胞癌(二线)、非鳞状非小细胞肺癌(一线联合)、食管鳞癌(二线)。

⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。

⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。

Associated Conditions
-
Associated Therapies
-

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-04-15
Last Posted Date
2023-09-18
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
233
Registration Number
NCT04346381
Locations
🇨🇳

Fudan University Zhongshan Hospital, Shanghai, Shanghai, China

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

First Posted Date
2020-04-13
Last Posted Date
2021-02-08
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
56
Registration Number
NCT04342936
Locations
🇨🇳

Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

First Posted Date
2020-04-13
Last Posted Date
2021-02-23
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
550
Registration Number
NCT04342910
Locations
🇨🇳

Affiliated Hospital, Academy of Military Medical Sciences, Beijing, China

Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen

First Posted Date
2020-04-09
Last Posted Date
2020-07-09
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
25
Registration Number
NCT04340401
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

First Posted Date
2020-04-07
Last Posted Date
2020-04-07
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
100
Registration Number
NCT04337606
Locations
🇨🇳

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2020-03-24
Last Posted Date
2024-07-17
Lead Sponsor
West China Hospital
Target Recruit Count
21
Registration Number
NCT04318730
Locations
🇨🇳

West China Hospital, Sichuan University, Chengdu, Sichuan, China

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2020-03-11
Last Posted Date
2023-04-12
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
46
Registration Number
NCT04303741
Locations
🇨🇳

The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

🇨🇳

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

🇨🇳

Changhai Hospital, Navy Medical University (Second Military Medical University), Shanghai, Shanghai, China

Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

Phase 2
Conditions
Interventions
First Posted Date
2020-03-10
Last Posted Date
2020-03-10
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
52
Registration Number
NCT04303130
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma

First Posted Date
2020-03-09
Last Posted Date
2023-09-13
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT04299581
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC(SHR-1210-AIN457)

Phase 1
Conditions
Interventions
First Posted Date
2020-03-06
Last Posted Date
2020-03-16
Lead Sponsor
Yanqiao Zhang
Target Recruit Count
40
Registration Number
NCT04298320
© Copyright 2024. All Rights Reserved by MedPath